title: [Clinical analysis of lymphoblastic lymphoma/leukemia treated with Hyper-CVAD/MA regimen chemotherapy combined with haploidentical hematopoietic stem cell infusion].
abstract: This study was aimed to investigate the efficacy of Hyper-CVAD/MA regimen chemotherapy combined with haploidentical hematopoietic stem cell infusion for the treatment of lymphoblastic lymphoma/leukemia (LBL/ALL). Seven patients with LBL/ALL were treated in Second Artillery General Hospital from August 2009 to September 2012. All patients received programmed infusions of granulocyte-colony stimulating factor (G-CSF)-mobilized family related HLA-haploidentical donor peripheral blood hematopoietic stem cell (G-PBHSC) after each of cycle of Hyper-CVAD/MA regimen chemotherapy without graft-versus-host disease (GVHD) prophylaxis. A total of four cycles of therapy were planned. The interval between each cycle of treatment was 8 to 12 weeks. By April 2014, the median follow-up time was 41 (20-57) months. The results showed that the 7 patients totally received 30 cycles of treatment, and all patients achieved complete remission (CR). The patients were generally well-tolerated to therapy, and the most significant toxicities of grade 3 to 4 neutropenia and thrombocytopenia developed in nearly all of the patients after each course of the Hyper-CVAD/MA regimen. No GVHD was observed in any of the patients during treatment. Up to now, 5 patients were still alive, 2 patients were died of relapse. It is concluded that the combination of chemotherapy and programmed haploidentical G-PBHSC infusion is a promising approach to the treatment of LBL/ALL.
authors.affiliation: Department of Hematology, The Second Artillery General Hospital, Beijing 100088, China. E-mail:sunwanjun1974@sohu.com.
authors.forename: Wan-Jun
authors.initials: WJ
authors.lastname: Sun
authors.affiliation: Department of Hematology, The Second Artillery General Hospital, Beijing 100088, China.
authors.forename: Hong-Xia
authors.initials: HX
authors.lastname: Zhao
authors.affiliation: Department of Hematology, The Second Artillery General Hospital, Beijing 100088, China.
authors.forename: Ya-Jing
authors.initials: YJ
authors.lastname: Huang
authors.affiliation: Department of Hematology, The Second Artillery General Hospital, Beijing 100088, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Hematology, The Second Artillery General Hospital, Beijing 100088, China.
authors.forename: Hui-Hui
authors.initials: HH
authors.lastname: Hou
authors.affiliation: Department of Hematology, The Second Artillery General Hospital, Beijing 100088, China.
authors.forename: Na-Na
authors.initials: NN
authors.lastname: Dai
authors.affiliation: Department of Hematology, The Second Artillery General Hospital, Beijing 100088, China.
authors.forename: Xiao-Qin
authors.initials: XQ
authors.lastname: Xi
authors.affiliation: Department of Hematology, The Second Artillery General Hospital, Beijing 100088, China.
authors.forename: Hai-Lan
authors.initials: HL
authors.lastname: Hu
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D003520:Cyclophosphamide / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D036102:Peripheral Blood Stem Cell Transplantation; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide